Aclidinium bromide (Tudorza Genuair - Almirall Canada Ltd.) indication: chronic obstructive pulmonary disease
CADTH
Record ID 32014000735
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that aclidinium bromide be listed for the treatment of chronic obstructive pulmonary disease (COPD) if the following conditions are met:
• List in a manner similar to other long-acting antimuscarinic antagonists (LAMAs).
• Drug plan costs for aclidinium bromide should not exceed the cost of any other LAMA.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/cdr_complete_SR0346_Tudorza%20Genuair_Ap_23_2014.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Muscarinic Antagonists
- Pulmonary Disease, Chronic Obstructive
- Tropanes
- Bronchodilator Agents
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.